SCHEMBL3756497

SCHEMBL3756497

CC(C)(O)C(=O)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
TDP1 Q9NUW8 3/20 0.53
KMT2A Q03164 2/20 0.53
MAPK1 P28482 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A3 Q01959 1/20 0.53
MEN1 O00255 1/20 0.51
LMNA P02545 3/20 0.49
HCAR2 Q8TDS4 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
MAOB P27338 1/20 0.46
PTPRC P08575 1/20 0.46
PTPN1 P18031 1/20 0.46
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24347012 0.89 ALDH1A1 (0.60) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL522510 0.86 ALDH1A1 (0.62) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL991531 0.86 ALDH1A1 (0.62) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL30441478 0.85 ALDH1A1 (0.56) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL8580399 0.85 ALDH1A1 (0.56) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL15114664 0.85 ALDH1A1 (0.56) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL1706652 0.85 ALDH1A1 (0.60) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Ammonia Solution, Strong SCHEMBL27451848 0.85 ALDH1A1 (0.60) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL28246707 0.85 ALDH1A1 (0.60) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL2032918 0.84 ALDH1A1 (0.55) ALDH1A1TDP1KMT2AMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof SYSTIMMUNE, INC. (US) 2026-03-17 US disclosed
EP-4595978-A1 ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF SystImmune, Inc. (US) 2025-08-06 EP disclosed
CN-120131991-A Anti-human Claudin18.2 antibody-camptothecine drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2025-06-13 CN disclosed
US-20250115679-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. (CN) 2025-04-10 US disclosed
US-20250059296-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF SYSTIMMUNE INC (US) 2025-02-20 US disclosed
CN-117752813-A anti-CD 33 antibodies and anti-CD 33 antibody-drug conjugates and uses thereof 成都百利多特生物药业有限责任公司 2024-03-26 CN disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 US disclosed
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SYSTIMMUNE, INC. 2023-07-20 US disclosed
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SYSTIMMUNE, INC. 2023-07-20 US disclosed
US-11702407-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed
US-20080009474-A1 PENEM PRODRUGS PFIZER INC 2008-01-10 US disclosed
WO-2008001212-A2 PENEM PRODRUGS PFIZER PRODUCTS INC. (US) 2008-01-03 WO disclosed
US-6242514-B1 CYCLIC PHOSPHATE OR PHOSPHONATE; HEAT AND OXIDATION STABILIZER ESPECIALLY FOR OLEFIN POLYMERS AND ENGINEERING THERMOPLASTICS SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2001-06-05 US disclosed
US-5914361-A IMPART HEAT STABILITY TO ORGANIC MATERIALS, INCLUDING POLYOLEFINS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-06-22 US disclosed
US-5830936-A THERMAL STABILIZERS FOR POLYOLEFINS AND ENGINEERING PLASTICS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-03 US disclosed
US-5348953-A Elastase inhibitor MERCK & CO., INC. (US) 1994-09-20 US disclosed
WO-1994013636-A1 NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS MERCK & CO., INC. (US) 1994-06-23 WO disclosed
CN-1068815-A Be used as the new substituted azetidinone of anti-inflammatory and antidegenerative agent MERCK & CO INC (US) 1993-02-10 CN disclosed
EP-0525973-A2 Substituted azetidinones as anti-inflammatory and antidegenerative agents MERCK & CO. INC. (US) 1993-02-03 EP disclosed
WO-1993000332-A1 SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS MERCK & CO., INC. (US) 1993-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702407-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 ALDH1A1 1727/4885TDP1 3649/4885KMT2A 2867/4885
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof IGLV6-57, EGFR, ERBB2 ALDH1A1 3799/4885TDP1 1675/4885KMT2A 2519/4885
US-20250115679-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF ANTXR2, PAICS, CD38 ALDH1A1 1919/4885TDP1 3050/4885KMT2A 3730/4885
US-20080009474-A1 PENEM PRODRUGS PGM2, PGLS, PMM2 ALDH1A1 2418/4885TDP1 4272/4885KMT2A 2221/4885
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SLC7A1, CD44, DCLRE1A ALDH1A1 2318/4885TDP1 2486/4885KMT2A 3696/4885
US-20250059296-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF ANTXR2, PAICS, CD38 ALDH1A1 1919/4885TDP1 3050/4885KMT2A 3730/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 ALDH1A1 1726/4885TDP1 4039/4885KMT2A 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.